FDA Approves Targeted Therapy Combination for Melanoma

0

Just over a month after approving a first-of-its-kind combination therapy for advanced melanoma, the U.S. Food and Drug Administration (FDA) has signed off on another drug combination to treat the disease.

Skin cancer screeningsThe FDA has approved a targeted therapy combination, Cotellic (cobimetinib) and vemurafenib, to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery. The therapy targets a certain type of abnormal gene: BRAF V600E or V600K mutation.

“Treatment for melanoma is advancing at a record pace, with numerous new and exciting options for patients,” says Elizabeth Buchbinder, MD, a physician with Dana-Farber’s Melanoma Treatment Center. “The landscape for metastatic melanoma has been changing dramatically in a setting where there were previously only a few treatments available.”

In early October 2015, the FDA approved the first cancer treatment to combine two immunotherapy drugs: ipilimumab (Yervoy) and nivolumab (Opdivo). The immunotherapeutic combination has been approved to treat certain patients with unresectable or metastatic melanoma. Specifically, it is approved for patients who have tumors that do not harbor the BRAF V600 mutations found in about 50 percent of melanomas.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image
Refresh

*

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Fact Check: Can Breast Implants Cause Cancer? https://t.co/0nkxWtiRPo https://t.co/XCaLusKhzO
Dana-Farber @danafarber
#DYK: While relatively uncommon, approximately 15,000 people in the U.S. are diagnosed w/ #biliarycancer each year.… https://t.co/Xrl4SPsm8u
Dana-Farber @danafarber
From young patient to college student, Hannah has been all smiles with the support of her family and caregivers:… https://t.co/oSxMljQOyZ

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.